NATALEE Trial Long-Term Results on Ribociclib Combination …
WEBJan 25, 2024 · Invasive disease–free survival continued to be significantly improved for patients with hormone receptor–positive, HER2-negative, early-stage breast cancer who received the CDK4/6 inhibitor ribociclib plus a nonsteroidal aromatase inhibitor compared with a nonsteroidal aromatase inhibitor alone.
Ribociclib Improves Survival in Advanced Breast Cancer
WEBOct 6, 2021 · Women with metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer overall than women treated with letrozole only, updated results from the MONALEESA-2 …
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
WEB1 day ago · The new indication joins ribociclib's previous approval for advanced or metastatic HR-positive, HER2-negative breast cancer in combination with an aromatase inhibitor or fulvestrant.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
WEBMar 9, 2022 · First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced...
Ribociclib plus Endocrine Therapy in Early Breast Cancer
WEBMar 20, 2024 · Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast...
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast Cancer
WEB3 days ago · The FDA has approved ribociclib (Kisqali) plus an aromatase inhibitor as adjuvant treatment for patients with hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer at high risk of recurrence, according to a press release from Novartis. 1. The dosing information included a once daily oral dose of ribociclib at 400 ...
FDA Approves Adjuvant Ribociclib (Kisqali) Plus an Aromatase …
WEB2 days ago · Youssef Rddad. On Sept. 17, the U.S. Food and Drug Administration (FDA) approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor for adults with hormone receptor (HR)-positive, HER2-negative stage II and stage III early breast cancer who are at a high risk for recurrence. The agency also approved the ribociclib and letrozole co-pack ...
FDA Approves Ribociclib for Early Breast Cancer Treatment With …
WEB2 days ago · Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer. 2 The approval was supported by the NATALEE (NCT03701334) trial, a randomized, open-label ...
Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as …
WEBApr 11, 2024 · The study demonstrates the effectiveness and safety of ribociclib in a real-world setting of Brazilian patients with HR+/HER2– advanced breast cancer with a higher rate of PFS at 12 months than in the MONALEESA-2 9-11 and MONALEESA-7 12 trials (77.6%, 74.53%, and 72.7%, respectively).
Ribociclib and endocrine therapy as adjuvant treatment in …
WEBJun 7, 2023 · Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. | Journal of Clinical Oncology. Meeting Abstract: 2023 ASCO Annual Meeting II. Free access. Breast Cancer—Local/Regional/Adjuvant. June 07, 2023.
Skip to content